EFFECTIVENESS AND RENAL SAFETY OF TAF/FTC/EVG/cobi IN REAL CLINICAL PRACTICE

A. Alcalá Soto[1],L. Jiménez Pichardo[1],P.Gómez Germá[1],A.Varas Pérez[1], C. Puivecino Moreno[1], I. Marin Ariza[1], MT Gómez de Travecedo-Calvo[1]
Hospital SAS Jerez de la Frontera,Pharmacy Sercice, Cádiz,Spain

Background

Tenofovir alafenamide (TAF) is a new molecule that is replacing to TDF-the original formulation of tenofovir (TDF)- because of its improved efficacy and safety profile in HIV patients.

Purpose

To analyze efficacy and renal safety of TAF/FTC/EVG/cobi antiretroviral therapy (ART) in real clinical practice.

Material and methods

- Retrospective study including all patients who started treatment with TAF/FTC/EVG/cobi.
- Patients were divided into **2 subgroups**: **naive** and **pretreated** with other ARTs patients.
- Effectiveness: **plasma-HIV RNA (viral load) and CD4-T-lymphocyte (CD4) cell** count were measured at baseline and after 6 month treatment. Viral load <20copies/ml was considered as effective.
- Safety: **glomerular filtration rate (GFR**) and urinary protein to creatinine ratio. **Renal involvement** was considered if **GFR <60ml/min**.

Results

98 patients were analyzed, mean age was 46 years

	NAIVE SUBGROUP	PRETEATED SUBGROUP
Patients number	8 patients (**8%**)	90 patients (**92%**)
Plasma-HIV RNA	**6/8 patients <20copies/ml** after therapy	68/90 <20copies/ml at baseline and after therapy; **22/90** patients **37500copies/ml** at baseline; **16/22 <20copies/ml** after therapy
Mean CD4 ratio	181 to 221cel/µL	623 to 700cel/µL
Mean GFR	115ml/min to 107.3ml/min (↓7%)	98.5ml/min without change

Conclusion

TAF/FTC/EVG/cobi therapy was described to be **effective and safe** in both naive and pretrated patients in clinical practice.

eahp european association of hospital pharmacists

Nº: 5PSQ-049